Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review.

Medicine - 1 May 2019

Sciarra Alessandro, Gentilucci Alessandro, Silvestri Ida, Salciccia Stefano, Cattarino Susanna, Scarpa Susanna, Gatto Antonio, Frantellizzi Viviana, Von Heland Magnus, Ricciuti Gian Piero, Del Giudice Francesco, Maggi Martina

Abstract excerpt

BACKGROUND: androgen receptor variant 7 (AR-V7) has been suggested as potential marker for treatment selection in men with metastatic castration-resistant prostate cancer (mCRPC). The aim of the present review is to critically analyze: frequency of the AR-V7 expression in mCRPC cases-impact of AR-V7 expression on abiraterone, enzalutamide, and taxane therapy. METHODS: we searched in the Medline and Cochrane...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androstenes
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bridged-Ring Compounds

Share to Drug Resistance, Neoplasm

Share to Nitriles

Share to Prostatic Neoplasms, Castration-Resistant

Share to Receptors, Androgen

Share to Taxoids

Source

Open in PubMed Open full text

Identifiers

PMID: 31083254
DOI: 10.1097/MD.0000000000015608
PMCID: PMC6531263

Genes

AR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review.PMID 31083254Read ↗

[AR-V7 Androgen Receptor Variant as a Predictor of Response to Androgen-receptor Targeting Agents Used to Treat Castration-refractory Metastatic Prostate Cancer].Semantic proximity Read ↗

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.Semantic proximity Read ↗

The Clinicopathological Characteristics of Androgen Receptor Splicing Variant 7 (AR-V7) Expression in Patients with Castration Resistance Prostate Cancer: A Systematic Review and Meta‐AnalysisSemantic proximity Read ↗

AR-V7 Positivity Varies with Circulating Tumor Cell (CTC) Enrichment and Novel CTC Enrichment Is Able to Reduce AR-V7 False PositivitySemantic proximity Read ↗

Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancerSemantic proximity Read ↗

Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.Semantic proximity Read ↗

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancerSemantic proximity Read ↗

Androgen Receptor Splice Variant 7 Detected by Immunohistochemical Is an Independent Poor Prognostic Marker in Men Receiving Adjuvant Androgen-Deprivation Therapy After Radical ProstatectomySemantic proximity Read ↗

Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.Semantic proximity Read ↗

Urinary Exosome Based Androgen Receptor Variant 7 Detection in Metastatic Castration Resistant Prostate Cancer PatientSemantic proximity Read ↗

AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.